Roles of PPARα and PPARγ As Regulator of Free Fatty Acids in Nonalcoholic Steatohepatitis
Preprint
- 14 April 2023
- preprint
- Published by MDPI AG in Preprints.org
Abstract
In recent years, nonalcoholic fatty liver disease/steatohepatitis (NAFLD/NASH) has become a leading worldwide disease, and its therapies are facing many complexities. Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors that belong to the nuclear receptor (NR) superfamily and have three subtypes: PPARα (NR1C1), PPARβ/δ (NR1C2), and PPARγ (NR1C3). They have been identified to be essential in the regulation of lipid metabolism by controlling the transcription of genes related to fatty acids, bile acids, and cholesterol metabolism. Many PPAR agonists have been reported, such as natural agonists (fatty acids, eicosanoids, and phospholipids) and synthetic ligands (fibrates, thiazolidinediones, glitazars, and elafibranor). PPAR-based chemicals have a breakthrough in the innovation of therapy for fatty liver disease. This review will provide an overview of how PPARα and PPARγ play roles in lipid homeostasis, discussing the consideration of their agonists as potential therapeutic agents for NAFLD/NASH.Keywords
All Related Versions
This publication has 103 references indexed in Scilit:
- Saroglitazar, a PPAR‐α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double‐Blind Phase 2 TrialHepatology, 2021
- The effects of resveratrol supplementation on PPARα, p16, p53, p21 gene expressions, and sCD163/sTWEAK ratio in patients with type 2 diabetes mellitus: A double‐blind controlled randomized trialPhytotherapy Research, 2021
- Nonalcoholic SteatohepatitisJAMA, 2020
- Insulin promotes macrophage phenotype transition through PI3K/Akt and PPAR‐γ signaling during diabetic wound healingJournal of Cellular Physiology, 2018
- Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver diseaseCellular and Molecular Life Sciences, 2018
- Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of diseaseHepatology, 2017
- The new‐generation pan‐peroxisome proliferator‐activated receptor agonist IVA337 protects the liver from metabolic disorders and fibrosisHepatology Communications, 2017
- Long-Term Efficacy of Rosiglitazone in Nonalcoholic Steatohepatitis: Results of the Fatty Liver Improvement by Rosiglitazone Therapy (Flirt 2) Extension TrialHepatology, 2010
- The Effects of Rosiglitazone, Metformin, and Diet with Exercise in Nonalcoholic Fatty Liver DiseaseDigestive Diseases and Sciences, 2007
- Ursodeoxycholic Acid or Clofibrate in the Treatment of Non–Alcohol–Induced Steatohepatitis: A Pilot StudyHepatology, 1996